Phase II/III ZOTRIP study of Qtrypta in migraine published in Headache journal.- Zosano Pharma

Zosano Pharma Corporation announced the peer-reviewed publication of a post-hoc analysis of its pivotal Phase II/III (ZOTRIP) study of Qtrypta (zolmitriptan-coated microneedle patch) in Headache: The Journal of Head and Face Pain, titled �Efficacy of ADAM Zolmitriptan for the Acute Treatment of Difficult to Treat Migraines.�

In this post-hoc analysis, researchers examined the efficacy of Qtrypta in treating subsets of patients whose migraines have traditionally been difficult-to-treat and have been associated with poorer outcomes when treated with oral medications. Migraine characteristics including severe pain, duration of migraine of more than 2 hours, awakening with migraine, and the presence of nausea are established factors that predict a poorer response to traditional migraine treatment. Results from these post-hoc analyses using the same clinical endpoints of pain freedom and most bothersome symptom (MBS) at 2 hours from the ZOTRIP study demonstrated patients with these difficult-to-treat migraine characteristics had uniformly better headache responses compared to patients who received placebo.

See: "Efficacy of ADAM Zolmitriptan for the Acute Treatment of Difficult-to-Treat Migraine Headaches" Stewart J. Tepper et al. Headache: The Journal of Head and Face PainFirst Published: 30 January 2019 https://doi.org/10.1111/head.13482